Hdm2 and nitric oxide radicals contribute to the p53-dependent radioadaptive response

Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):550-8. doi: 10.1016/j.ijrobp.2008.02.001. Epub 2008 Apr 12.

Abstract

Purpose: The aim of this work was to characterize the radioadaptive response at the molecular level.

Methods and materials: We used wild-type (wt) p53 and mutated (m) p53-containing cells derived from the human lung cancer H1299 cell line, which is p53-null. Cellular radiation sensitivities were determined with a colony-forming assay. The accumulations of p53, the human homolog of endogenous murine double minute 2 (Hdm2), and inducible nitric oxide synthase were analyzed with Western blotting. Quantification of chromosomal aberrations was estimated by scoring dicentrics per cell.

Results: In wtp53 cells, it was demonstrated that the lack of p53 accumulation was coupled with the activation of Hdm2 after low-dose irradiation (0.02 Gy). Although NO radicals were only minimally induced in wtp53 cells irradiated with a challenging irradiation (6 Gy) alone, NO radicals were seen to increase about two- to fourfold after challenging irradiation subsequent to a priming irradiation (0.02 Gy). Under similar irradiation conditions with a priming and challenging irradiation in wtp53 cells, induction of radioresistance and a depression of chromosomal aberrations were observed only in the absence of 5, 5'-(2, 5-Furanidiyl)bis-2-thiophenemethanol (RITA) or Nutlin-3 (p53-Hdm2 interaction inhibitors), aminoguanidine (an inducible nitric oxide synthase inhibitor), and c-PTIO (an NO radical scavenger). On the other hand, in p53 dysfunctional cells, a radioadaptive response was not observed in the presence or absence of those inhibitors. Moreover radioresistance developed when wtp53 cells were treated with isosorbide dinitrate (an NO-generating agent) alone.

Conclusions: These findings suggest that NO radicals are initiators of the radioadaptive response, acting through the activation of Hdm2 and the depression of p53 accumulations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Cell Survival
  • Chromosome Aberrations
  • Cyclic N-Oxides / pharmacology
  • Free Radical Scavengers / pharmacology
  • Genes, p53 / genetics*
  • Guanidines / pharmacology
  • Humans
  • Imidazoles / pharmacology
  • Nitric Oxide / pharmacology
  • Nitric Oxide Synthase / pharmacology
  • Nitric Oxide Synthase Type II / antagonists & inhibitors
  • Nitric Oxide Synthase Type II / metabolism*
  • Piperazines / pharmacology
  • Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors
  • Proto-Oncogene Proteins c-mdm2 / metabolism*
  • Proto-Oncogene Proteins c-mdm2 / radiation effects
  • Radiation Tolerance / genetics
  • Radiation Tolerance / physiology*
  • Time Factors
  • Tumor Suppressor Protein p53 / antagonists & inhibitors
  • Tumor Suppressor Protein p53 / metabolism*

Substances

  • Cyclic N-Oxides
  • Free Radical Scavengers
  • Guanidines
  • Imidazoles
  • Piperazines
  • Tumor Suppressor Protein p53
  • 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide
  • Nitric Oxide
  • nutlin 3
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • MDM2 protein, human
  • Proto-Oncogene Proteins c-mdm2
  • pimagedine